RedHill Biopharma's Opaganib Demonstrates Significant Decrease...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
TEL AVIV, Israel and RALEIGH, N.C., Sept. 7, 2021 /PRNewswire-AsiaNet/ -- - COVID-19 and long COVID patients are at increased risk of developing kidney damage- Opaganib significantly decreased kidney fibrosis in a preclinical in vivo model- Renal fibrosis is a progressive process which occurs in patients with chroni...
Authors: LATEST ASIANET NEWS RELEASES